131738-73-3

Basic information

• Product Name: 1-BROMO-3-ISOPROPOXYBENZENE
• Synonyms: ISOPROPYL 3-BROMOPHENYL KETONE;2-(3'-BROMOPHENOXY)PROPANE;2-(3-BROMOPHENOXY)PROPANE;3-BROMOPHENYL ISOPROPYL ETHER;3-BROMOPHENYL ISOPROPYL KETONE;3-BROMOISOPROPOXYBENZENE;3-ISOPROPOXY-1-BROMOBENZENE;2-(3-Bromophenoxy)propane~3-Bromophenyl isopropyl ether
• CAS NO: 131738-73-3
• Molecular Formula: C₉H₁₁BrO
• Molecular Weight: 215.09
• Product Categories: Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds
• Mol File: 131738-73-3.mol

Chemical Properties

• Boiling Point: 222 °C(lit.)
• Flash Point: 228 °F
• Appearance: /
• Density: 1.331 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0919mmHg at 25°C
• Refractive Index: n20/D 1.539(lit.)
• Storage Temp.: 2-8°C
• BRN: 4176950
• CAS DataBase Reference: 1-BROMO-3-ISOPROPOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3-ISOPROPOXYBENZENE(131738-73-3)
• EPA Substance Registry System: 1-BROMO-3-ISOPROPOXYBENZENE(131738-73-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 131738-73-3(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C9H11BrO/c1-7(2)11-9-5-3-4-8(10)6-9/h3-7H,1-2H3

Upstream product

• 591-20-8 3-Bromophenol 
• 75-26-3 isopropyl bromide 
• 591-18-4 1-Bromo-3-iodobenzene 
• 67-63-0 isopropyl alcohol 
• 89598-96-9 (3-bromophenyl)boronic acid 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 75-30-9 2-iodo-propane 

Downstream Products

• 172376-39-5 cis-(+/-)-1,3-dimethyl-4-<3-(1-methylethoxy)phenyl>-4-piperidinol 
• 915190-56-6 C₁₈H₁₅NOS 
• 915190-62-4 C₁₈H₁₉ONS 
• 1079883-92-3 2-(3-isopropoxyphenyl)-quinoline 
• 1160526-81-7 5-(3-isopropoxyphenyl)-3-methyl-5-phenylfuran-2-one 
• 172376-39-5 cis-(+/-)-1,3-dimethyl-4-[3-(1-methyl-ethoxy)phenyl]-4-piperidinol 
• 172376-39-5 C₁₆H₂₅NO₂ 
• 1310329-89-5 (R)-benzyl (2-(tert-butylsulfinyl)-6-isopropoxyphenyl) sulfane 
• 1310329-92-0 C₁₃H₂₀O₂S 
• 1374584-28-7 bis(4-(iso-propoxy)phenyl)pyridin-3-yl methanol 
• 1374583-98-8 (4-chlorophenyl)(3-(propan-2-yloxy)phenyl)pyridin-3-yl methanol 
• 172376-39-5 C₁₆H₂₅NO₂ 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Organometallic compound and organic light-emitting device including the same

Organic metal compound and said organometallic compounds is disclosure is an organic light emitting device. (by machine translation)

Base Mediated Synthesis of Alkyl-aryl Ethers from the Reaction of Aliphatic Alcohols and Unsymmetric Diaryliodonium Salts

The base mediated coupling of aliphatic alcohol pronucleophiles with unsymmetric diaryliodonium salt electrophiles is described. This metal-free reaction is operationally simple, proceeds at mild temperature, and displays broad substrate scope to generate industrially important alkyl-aryl ethers in moderate to excellent yield. The synthetic utility of these reactions is demonstrated, and aspects of sustainability are highlighted by the use of unsymmetric aryl(mesityl)iodonium arylating reagents.

Analogues of fenarimol are potent inhibitors of trypanosoma cruzi and are efficacious in a murine model of chagas disease

We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC50s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.

Solid dispersions of opioid antagonists

Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.

Compositions containing opioid antagonists

Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of processing techniques and component selection.

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

Compositions containing opioid antagonist

Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.

Use of tunable ligands allows for intermolecular Pd-catalyzed C-O bond formation

Bulky biaryl phosphine ligands facilitate Pd-catalyzed C-O coupling reactions of aryl halides with primary and secondary alcohols by promoting reductive elimination at the expense of β-hydride elimination. The key to their success is the ability to match the size of the ligand to that of the combination of substrates. The efficient coupling of a number of unactivated aryl chlorides and bromides with cyclic and acyclic secondary alcohols was achieved. This included the coupling of allylic alcohols for the first time in a Pd-catalyzed coupling process.